Quarterly ResultMay 5, 2026, 04:15 PM
Schrodinger Q1 Net Loss $(60.0)M; Operating Cash Flow Negative
AI Summary
Schrodinger, Inc. reported a net loss of $(60.0) million for the first quarter of 2026, a slight increase from $(59.8) million in the prior year period. Total revenues decreased by 1.6% to $58.6 million, primarily due to a 20.9% decline in software products and services revenue. This was partially offset by a substantial 123.5% increase in drug discovery revenue. The company also experienced a significant swing in operating cash flow, moving from $144.1 million provided in Q1 2025 to $(14.8) million used in Q1 2026.
Key Highlights
- Net loss for Q1 2026 was $(60.0) million, compared to $(59.8) million in Q1 2025.
- Total revenues decreased 1.6% to $58.6 million in Q1 2026 from $59.6 million in Q1 2025.
- Software products and services revenue declined 20.9% to $35.6 million in Q1 2026.
- Drug discovery revenue increased 123.5% to $22.9 million in Q1 2026.
- Net cash used in operating activities was $(14.8) million in Q1 2026, a significant shift from $144.1 million provided in Q1 2025.
- Cash, cash equivalents, restricted cash, and marketable securities totaled $406.4 million as of March 31, 2026.
Price Impact
More from SDGR